news Celltrion selects 14 lead monoclonal antibodies for COVID-19 treatment 16 April 2020 | By Victoria Rees (Drug Target Review) After screening 300 antibodies, Celltrion has identified the 14 most powerful that could potentially combat the COVID-19 coronavirus.
news Researchers reveal how remdesivir prevents COVID-19 viral replication 15 April 2020 | By Victoria Rees (Drug Target Review) According to a new study, the drug remdesivir is a very potent inhibitor for coronavirus polymerases - demonstrating its potential for combatting COVID-19.
news COVID-19 Drug Repurposing Database made open-access by Excelra 15 April 2020 | By Hannah Balfour (Drug Target Review) The enterprise revealed that it has made its COVID-19 Drug Repurposing Database open-access to aid in the search for an effective therapeutic.
news Main COVID-19 protease revealed, enabling screening of potential drugs 14 April 2020 | By Victoria Rees (Drug Target Review) Chinese researchers who determined the crystal structure of the COVID-19 protease Mpro used this information to screen over 10,000 compounds to combat the coronavirus.
article Mesenchymal stem cells secretome as a prospective therapeutic option for COVID-19 patients 13 April 2020 | By Avinash Kharat (Dr D Y Patil Vidyapeeth), Avinash Sanap ( Dr D Y Patil Vidyapeeth), Dr Ramesh Bhonde (Dr D Y Patil Vidyapeeth), Supriya Kheur (Dr D Y Patil Vidyapeeth) Researchers propose using mesenchymal stem cells to counter the pro-inflammatory cytokines associated with COVID-19 coronavirus symptoms.
news EIDD-2801 shows efficacy against COVID-19 in human cells and mice 7 April 2020 | By Hannah Balfour (Drug Target Review) Collaborators have shown that the broad spectrum oral antiviral EIDD-2801 could be a potential prophylactic or therapeutic for COVID-19 and other coronaviruses.
news Researchers reveal how SARS antibody binds to COVID-19 coronavirus 7 April 2020 | By Victoria Rees (Drug Target Review) The interaction between a SARS antibody called CR3022 and the COVID-19 coronavirus has been mapped by researchers, revealing a viral vulnerability.
news Celltrion to select lead antibody candidates to fight COVID-19 6 April 2020 | By Victoria Rees (Drug Target Review) Following the screening of antibodies, Celltrion will now identify the most potent out of 300 hits that work against the COVID-19 coronavirus best.
news Collaboration to develop inhaled mRNA-based antibody therapy for COVID-19 6 April 2020 | By Hannah Balfour (Drug Target Review) Two companies, Neurimmune and Ethris, will leverage their technologies to research, develop and produce an inhaled therapy for COVID-19.
news Ivermectin shows activity against COVID-19 in cell cultures 6 April 2020 | By Hannah Balfour (Drug Target Review) A study has demonstrated that the anti-parasitic drug ivermectin may be effective against SARS-CoV-2, the virus which causes COVID-19.
news Decoy ACE2 receptors could be promising COVID-19 infection-preventing drug 3 April 2020 | By Hannah Balfour (Drug Target Review) Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
news AI technology to screen existing drugs for use against COVID-19 2 April 2020 | By Victoria Rees (Drug Target Review) A collaboration aims to utilise a compound library of 15,000 clinically-ready molecules and screen then against three COVID-19 targets.
news COVID-19 update: funding for treatments and vaccines 1 April 2020 | By Victoria Rees (Drug Target Review) Drug Target Review rounds up the latest announcements regarding funding for research into COVID-19 treatments and vaccines.
news Nafamostat inhibits SARS-CoV-2 infection, preventing COVID-19 transmission 31 March 2020 | By Hannah Balfour (Drug Target Review) Researchers have demonstrated that Nafamostat mesylate (Fusan) can inhibit SARS-CoV-2 Spike protein-initiated membrane fusion at concentrations likely achievable and safe in patients.
news Novel antiviral compound proposed as COVID-19 therapeutic 30 March 2020 | By Victoria Rees (Drug Target Review) A molecule called BOLD-100, developed to fight cancer, has been suggested as a therapeutic to combat the COVID-19 coronavirus due to its antiviral properties.
